drugset / Press release
Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
2020-09-14 · Moleculin Biotech, Inc. · original moleculin.com ↗
HOUSTON, Sept. 14, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has contracted with an independent laboratory to test the antiviral activity of its WP1122 portfolio in a COVID-19 animal model.
The release as fetched from its publisher. moleculin.com ↗